EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis

Brandon Smith, Michael R Collier, Jashin J Wu

JAMA · 2023

DOI: 10.1001/jama.2022.22646 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Brandon Smith und 2 weiteren Autor:innen. Beteiligte Einrichtung: Drexel University College of Medicine, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsPsoriasisHumansAminopyridinesBenzamidesChronic DiseaseCyclopropanesDouble-Blind MethodSeverity of Illness IndexSkin CreamTreatment OutcomeAdministration, Cutaneous

Substanzen

AminopyridinesBenzamidesCyclopropanesPhosphodiesterase 4 InhibitorsRoflumilast

Autor:innen und Institutionen

  • Drexel University College of Medicine, Philadelphia, Pennsylvania.
  • USF Health Morsani College of Medicine, Tampa, Florida.
  • University of Miami Miller School of Medicine, Miami, Florida.

Zitieren

APA

Smith, B., Collier, M. R., & Wu, J. J. (2023). Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis. JAMA. https://doi.org/10.1001/jama.2022.22646

Vancouver

Smith B, Collier MR, Wu JJ. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis. JAMA. 2023. doi:10.1001/jama.2022.22646

BibTeX
@article{Smith2023,
  author = {Smith, Brandon and Collier, Michael R and Wu, Jashin J},
  title = {Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2022.22646}
}
Kostenlos starten →